Biotech for less than a buck. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (199)	12/2/1999 8:48:00 AM
From: Softechie	Read Replies (1) of 743

Avanir has put out a new SEC filing couple days ago on the bridge loan and other info. Avanir is on the right track. It's in its infancy stage. When revenue starting to streaming in next year, you'll see how good it will be. Why would there be 8 companies trying to get in bed with Avanir? It's scaring Devanir and Zovirax market. These are RX products. FDA won't allow these products to be in OTC. So why did FDA allow Docosanol to be in OTC market? Because it works beautifully. Dr. Katz is an excellent scientist but not a very good director. Avanir next 2 steps are site auditing and labeling agreement. Do you feel it's 90% there for an official approval? After getting the approval status and got a marketing partner, is there anything in the way for Docosanol to be on your nearest drug stores? Avanir past history is a bit less desirable but now our future is bright. Let's move on.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next